It was reported that a combination of anti-4.1BB antibody with Trp2 peptides and CpG-ODN induced antigen-specific IFN-γ, and CD8+ CTL responses significantly increased up to 75% anti-tumor cure rate, highlighting the importance of TLR9 agonist combination with 4.1BB blockade for achieving tumor eradication38. This evidence concerns the gene TLR9 and neoplasm.